Y-Intercept (HK)
MAZE icon

Y-Intercept (HK)’s Maze Therapeutics MAZE Stock Holding History

Y-Intercept (HK)’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.55M Buy
57,125
+42,755
+298% +$1.19M 0.03% 758
2026
Q2 		$429K Sell
14,370
-7,358
-34% -$193K 0.01% 1357
2026
Q1 		$649K Buy
+21,728
New +$959K 0.01% 1195

Other funds holding MAZE

Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Y-Intercept (HK)'s MAZE Position: Q3 2026 in Review

Y-Intercept (HK) increased its Maze Therapeutics (MAZE) stake by 298% in Q3 2026, buying an estimated $1.19M and bringing the position to 57,125 shares worth $1.55M. The position accounts for 0.03% of the portfolio, ranked #758.

Y-Intercept (HK) first reported a position in MAZE in Q1 2026 and has held it in 3 quarters since. 9 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • Y-Intercept (HK) held 57,125 shares of Maze Therapeutics worth $1.55M as of Q3 2026.
  • Y-Intercept (HK) bought 42,755 Maze Therapeutics shares in Q3 2026, an estimated $1.19M.
  • Maze Therapeutics made up 0.03% of Y-Intercept (HK)'s portfolio in Q3 2026, its #758 holding.
  • Y-Intercept (HK) first reported a position in Maze Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 9 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.